メインコンテンツにスキップ
検索
展示会・学会

2025 ISPE Annual Meeting

Conference: 2025 ISPE Annual Meeting

開催日: August 22 - 26, 2025

開催場所: Washington, DC

Booth: 303

Learn more about Certara’s innovative approach to studying rare diseases

Addressing complex challenges associted with rare disease drug development and evidence generation requires an innovative approach. Visit Certara at booth #303 at the 2025 ISPE Annual Meeting to connect with our real-world evidence and pharmacoepidemiology experts to hear more about we’re linking rare disease registries with national health claims databases to overcome issues related to limited and incomplete data and help our customers assess the burden of illness.

Linking data to solve common yet complex challenges in studying rare disease

Certara’s experts can help you overcome:

  • Limited data availability due to rarity of condition
  • Locating small and dispersed patient populations
  • Incomplete data sources that lack all necessary variables to study, e.g., certain outcomes and resource utilization, but not granular clinical measures or quality of life

Where to hear Certara insights and expertise

日付：Sunday, August 24
開催時間：12 – 1:30 p.m. ET
Poster: (A-303) Evolution of the treatment landscape for patients diagnosed with amyotrophic lateral sclerosis in the United States

Presenting author: Artak Khachatryan

Co-author(s): Malgorzata Ciepielewska, Aastha Chandak, Alekhya Lavu, Polina DaSilva

日付：Tuesday, August 26
開催時間：12 – 1:30 p.m. ET
Poster: (C-190) Disease burden and unmet needs of patients with amyotrophic lateral sclerosis in the United States.

Presenting author: Alekhya Lavu

Co-author(s): Malgorzata Ciepielewska, Aastha Chandak, Polina DaSilva, Gaelle Gusto, Vishnu Sarda, Kalyani Kankanampati, Artak Khachatryan

Explore Certara's RWE Services

  • Outcomes Research and Surveys: Analyzing treatment patterns, patient outcomes, and unmet needs in niche populations to inform development and market access strategies
  • Data Source Selection: Identifying and selecting the most appropriate real-world data sources (e.g., patient registries, medical records, claims data) to address specific research questions
  • Advanced Analytics and Modeling: Applying sophisticated analytical techniques to RWE to extract meaningful insights, including comparative effectiveness studies, cost-effectiveness analyses, and safety evaluations.
  • Regulatory Support: Providing regulatory writing, strategy, and submission expertise to support rare disease drug approvals.
  • Market Access Strategies: Developing strategies to optimize pricing, reimbursement, and market access for rare disease therapies.

Additional Resources

関連コンテンツ

Early Systematic PICO Scenario Identification and Prioritization for EU HTA Joint Clinical Assessments
Early Systematic PICO Scenario Identification and Prioritization for EU HTA Joint Clinical AssessmentsPoster

Early Systematic PICO Scenario Identification and Prioritization for EU HTA Joint Clinical Assessments

Supporting KalVista’s NDA Submission for a Novel HAE Treatment​
Supporting KalVista’s NDA Submission for a Novel HAE Treatment​Case Study

Supporting KalVista’s NDA Submission for a Novel HAE Treatment​

Failure to Launch: Building Smarter Strategies to Get the Right Drug to the Right Patient
Failure to Launch: Building Smarter Strategies to Get the Right Drug to the Right PatientWebinar

Failure to Launch: Building Smarter Strategies to Get the Right Drug to the Right Patient

Powered by Translations.com GlobalLink Web Software